Current Drug Targets - Online First
Description text for Online First listing goes here...
28 results
-
-
Targeting the Toll-like Receptor Signaling Pathway in Lung Cancer: Therapeutic Opportunities and Challenges
Authors: Muhammad Usama, Badar Raza, Mingfei Wu and Shanming JiAvailable online: 03 November 2025More LessLung cancer, particularly non-small cell lung cancer, is a leading cause of global mortality, with many cases diagnosed at advanced stages. The Toll-Like Receptor (TLR) signaling pathway plays a crucial role in linking inflammation to lung cancer progression, with both pro-tumor and anti-tumor effects. This perspective delves into the complex functions of TLR proteins in lung cancers, elucidating their involvement in tumor growth, angiogenesis, and metastasis. In addition, we highlight the therapeutic potentials of TLR agonists and antagonists, emphasizing their interplay with immune checkpoint inhibitors like PD-1/PD-L1 blockers to overcome immunosuppressive barriers. Nevertheless, the paradoxical effects of TLR activation, balancing immune stimulation and suppression, demand precise targeting strategies. Collectively, our study synthesizes the current understanding of TLR signaling pathways in lung cancers, offering insights into their potential for advancing lung cancer therapies.
-
-
-
The Emerging Landscape of LINC01123 in Cancer: Roles, Mechanisms, and Clinical Significance
Authors: Jingjie Yang, Fan Peng, Haodong He, Haoran Liu, Kexing Liu, Zhouya Xu, Yaqi Hu, Guihua Liao, Yan Cai and Chengfu YuanAvailable online: 11 September 2025More LessIntroductionLong intergenic non-coding RNA 01123 (LINC01123) is a lncRNA located on the human chromosome 2q13. It is upregulated in various cancers and has been identified as an oncogene. Its expression is associated with the risk and poor prognosis of multiple cancers.
MethodsA systematic literature search was conducted in PubMed, Web of Science, and Google Scholar databases using “LINC01123” as the search term. The retrieved studies were reviewed to analyze the expression patterns, oncogenic mechanisms, and clinical significance of LINC01123 in cancers.
ResultsLINC01123 is activated by transcription factors such as c-Myc, ZEB1, and FOXC1. It promotes cancer progression, metastasis, and drug resistance by acting as a “molecular sponge” for miRNAs, activating signaling pathways, or interacting with proteins. Its upregulation correlates with adverse clinicopathological features and poor prognosis in multiple cancers.
DiscussionThe findings suggest that LINC01123 plays a multifaceted role in cancer biology. Its ability to regulate gene expression through various mechanisms highlights its potential as both a prognostic biomarker and a therapeutic target. However, further research is needed to elucidate its mechanisms fully and to explore its clinical applications across different cancer types.
ConclusionLINC01123 has potential as a novel prognostic biomarker and therapeutic target for cancer. Further research is needed to elucidate its mechanisms and clinical applications fully.
-
-
-
Tachykinin Receptors and Their Antagonists: Unraveling Their Role in Metabolic Disorders and Therapeutic Innovations
Authors: Waquar Ahsan, Sadique A. Javed, Asim Najmi and Khalid ZoghebiAvailable online: 11 September 2025More LessIntroductionMetabolic disorders are major global health concerns with increasing prevalence worldwide. Experimental evidence suggests the role of tachykinins and their receptors in metabolic regulation, neuroendocrine control, and inflammatory responses. This review aims to explore the implications of tachykinin receptors and their antagonists in the management of metabolic disorders.
MethodsA comprehensive literature search was performed across major scientific databases to identify and analyze preclinical and clinical studies on tachykinin receptors and their antagonists in the context of metabolic disorders. The key mechanisms of action of drugs, important therapeutic outcomes, and challenges associated with drug development were covered.
ResultsThe reported experimental and clinical studies suggest that the antagonists of NK1R, NK2R, and NK3R could influence glucose metabolism, lipid homeostasis, and appetite regulation. While NK1R antagonists, such as aprepitant, demonstrated anti-inflammatory and neuroprotective effects, NK3R antagonists, including fezolinetant, showed promise in modulating energy balance and thermoregulation.
DiscussionThese studies emphasized the emerging potential of tachykinin receptors and their antagonists in the management of metabolic dysfunctions. However, the challenges associated with its clinical translation, including receptor redundancy, limited biomarker-based patient stratification, and variations in receptor expression across species, are still relevant and need to be addressed to improve therapeutic outcomes.
ConclusionTachykinin receptor antagonists hold significant potential as therapeutic agents in the management of metabolic disorders. Further studies are warranted to overcome translational barriers, address safety issues, validate biomarkers, and refine receptor selectivity to achieve maximum therapeutic benefits.
-
-
-
Unraveling the Pivotal Role of LncRNA DUXAP9 in Cancer: Current Progress and Future Perspectives
Authors: Jingjie Yang, Siqi Yang, Wenjin Peng, Haodong He, Haoran Liu, Jiahe Zhang, Guihua Liao and Chengfu YuanAvailable online: 11 September 2025More LessDouble homeobox A pseudogene 9 (DUXAP9), also known as long intergenic non-coding RNA 1296 (LINC01296) and lymph node metastasis-associated transcript 1 (LNMAT1), is an emerging lncRNA encoded by a pseudogene. It has been reported to be upregulated in various tumor types and functions as an oncogenic factor. The high expression of DUXAP9 is closely related to clinical pathological features and poor prognosis in 16 types of malignant tumors. DUXAP9 is transcriptionally activated by YY-1 and Twist1 and functions as a guide or scaffold for biomolecular complexes and chromatin modifiers, or as a "decoy" for miRNAs, mRNAs, and proteins, thereby regulating gene expression. Moreover, the PI3K/AKT, NF-κB, MAPK/ERK, and Wnt/β- catenin signaling pathways are variously activated or inhibited by DUXAP9, subsequently influencing the biological behaviors of tumor cells, including proliferation, apoptosis, cell cycle arrest, migration, invasion, epithelial-mesenchymal transition (EMT), and drug resistance. This review summarizes recent research on DUXAP9 in oncology, offering insights into its expression characteristics, biological functions, molecular mechanisms, and clinical significance for cancer diagnosis, treatment, and prognosis.
-
-
-
Personalised Transdermal Therapy for Chronic Pain with Digital Twin Technology
Available online: 10 September 2025More LessDigital twin technology has emerged as a breakthrough development in healthcare, providing personalised transdermal drug delivery systems for chronic pain treatment. Digital twins provide accurate, customised therapy to enhance therapeutic outcomes and reduce risks by combining patient-specific computational models. This article aims to explore the applicability of digital twin technology in improving the transdermal delivery of drugs for successful chronic pain management. It is enabling personalised treatment through patient-specific simulations. By integrating physiological data with computational models, digital twins optimise drug absorption, patch application, and dosage adjustments in real-time, enhancing therapeutic outcomes while minimising side effects. Recent advancements highlight improvements in fentanyl patch optimisation, site-specific drug delivery, and thermally controlled systems. However, challenges such as ethical concerns, data security, and standardisation need to be addressed. Future research should focus on integrating AI and IoT to refine digital twin applications in precision medicine. It can be concluded from the findings of various studies that digital twin technology offers a promising future for precise and individualised transdermal drug delivery in chronic pain, paving the way for safer and more effective therapeutic interventions.
-
-
-
Novel Glitazones Protect Rotenone-induced Parkinsonism in Mouse Models by Targeting PGC1α
Available online: 08 September 2025More LessIntroductionParkinson’s disease (PD) is a persistent neurodegenerative condition marked by rising global rates of disability and mortality, warranting the need for new treatment options. The present investigation evaluated the protective effects of novel glitazones C7 and C25 against rotenone-induced PD in a mouse model.
MethodsMolecular docking using Discovery Studio and molecular dynamics simulations were employed to evaluate the binding ability of C7 and C25 to the PGC-1α target protein. Pharmacokinetic evaluations of C7 and C25 were performed against the standard pioglitazone in the rats model, and acute toxicity assessments were conducted following OECD guidelines 423. The neuroprotective effects of C7 were tested in a rotenone-induced mouse model of PD at doses of 10, 20, and 30 mg/kg body weight. Behavioral studies, including locomotor activity, grip strength, and catalepsy, as well as biochemical analyses such as endogenous antioxidant levels and AChE levels, were assessed.
ResultsThe novel compound C7 demonstrated good binding and simulation at the PGC-1α target protein. The kinetic profile of C7 was found to be good when compared to C25. Both the novel glitazones were safe at 300 mg/kg body weight when tested for oral acute toxicity. The novel compound C7 effectively alleviated symptoms related to rotenone-induced PD, demonstrating its promise as a therapeutic candidate.
DiscussionIn the rotenone-induced mouse model, compound C7 exhibited a promising anti-PD effect by attenuating oxidative stress and increasing muscular activity, which merits further investigations.
ConclusionAdditional research using various induction models, along with further investigation of cellular and molecular markers in larger animal studies, is needed to validate these findings.
-
-
-
Sepsis-Associated Brain Dysfunction: Mechanisms, Clinical Insights, and Therapeutic Strategies
Available online: 02 September 2025More LessSepsis is a lethal clinical condition representing severe inflammation and immune suppression to pathogen or infection, leading to tissue damage or organ dysfunction. Hyper-inflammation and immune suppression cause a fatal, escalated Blood-Brain Barrier permeability, being a secondary response towards infection resulting in sepsis-associated brain dysfunction. These changes in the BBB lead to the brain’s susceptibility to increased morbidity and mortality. An important mechanism of sepsis-associated brain dysfunction includes excessive activation of microglial cells, altered brain endothelial barrier function, and BBB dysfunction. Lipopoly- saccharide, a bacterial cell wall component (endotoxin), by forming a complex through membrane-bound CD receptors on macrophages, monocytes, and neutrophils, begins synthesizing anti-inflammatory agents for defense of the host, including nitric oxide, cytokines, chemokines, interleukins, and the complement system. Unrestrained endotoxemia and pro-inflammatory cytokines result in microglial as well as brain endothelial cell stimulation, downregulation of tight junctions, along with intense recruitment of leucocytes. Subsequent neuroinflammation, together with BBB dysfunction, aggravates brain pathology as well as worsens sepsis-associated brain dysfunction. The clinical demonstration includes mild (confusion and delirium) along with severe (cognitive impairment, coma, as well as sequel death). Different clinical neurophysiological evaluation parameters can be used for the quantification and important issues of the disorder, including SOFA, imaging methods, and the use of biomarkers associated with brain dysfunction. The present review addresses the mechanism, clinical examination, the long-term cognitive effects, and current treatment modalities for sepsis-associated brain dysfunction.
-
-
-
A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy
By Sangmin LeeAvailable online: 29 August 2025More LessAmylin is a thirty-seven amino acid peptide hormone that is secreted from the pancreas with insulin. The peptide hormone amylin activates its receptors in the brain to regulate blood glucose and food appetite. Interestingly, the amylin receptor is the heterodimer of the calcitonin receptor (which is the receptor for the peptide hormone calcitonin) and an accessory protein called receptor activity-modifying protein. Amylin receptor activation has emerged as a promising drug target for the treatment of diabetes and obesity. Recent pharmaceutical efforts with amylin receptor activators have focused on developing drugs for the treatment of obesity. Multiple amylin analogs have been tested in pre-clinical settings, and some are currently being tested in clinical trials. For this review, recent research publications and available information regarding drug development targeting amylin receptors were collected. This review summarizes the amylin receptor activators currently being tested in clinical trials for the treatment of obesity. In addition, recent research achievements were demonstrated, such as the introduction of mutations that enhanced receptor affinity/potency and the development of a method for measuring selective amylin receptor activation. Potential issues along with peptide drug development were described, including lipidation to achieve a long-acting property. The combination of an amylin analog and other anti-obesity peptide drugs has demonstrated higher clinical efficacy in reducing body weight than monotherapy. The combination therapy is likely to be the first drug therapy where an amylin analog is used for obesity treatment. In addition, amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators, which could be a potential benefit of amylin receptor activators.
-
-
-
Betaine, a Potential Therapeutic Alternative for the Treatment of Depression
Authors: Yue-Yue Zhang, Yuan-Yuan Cheng and Wei GuanAvailable online: 27 August 2025More LessDepression is a debilitating psychiatric disorder characterized by loss of interest, anhedonia, and social isolation, which is projected to become the leading cause of disability worldwide by 2030. Despite the greater economic and social burden imposed by depression, the precise pathophysiology underlying the development of depression remains elusive. Betaine (N, N, N-trimethylglycine), an amino acid derivative, is widely distributed in various animals and plants and has been shown to have numerous beneficial effects, including antioxidant activities, anti-inflammatory functions, regulation of energy metabolism, and reduction of endoplasmic reticulum stress. It has been used to treat Alcohol-Associated Liver Disease (AALD), type 2 diabetes, cancer, obesity, and Alzheimer's Disease (AD). Interestingly, accumulating evidence has shown that betaine exerts a significant role in alleviating depressive-like behavior in patients and animals resulting from chronic stress. Although the antidepressant effects of betaine have not been compared with traditional antidepressants with insufficient verification, based on the neurobiological mechanisms of depression, it may be a potential alternative medicine for the treatment of depression. This is the first review aiming to provide a comprehensive overview of the remarkable effects of betaine in the pathophysiology of depression. These pieces of evidence are of great importance for deepening our understanding of the antidepressant mechanism of betaine, so as to develop betaine supplements for the supplementary treatment of depression.
-
-
-
Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders
Authors: Varsha Harle and Yogeeta O. AgrawalAvailable online: 06 August 2025More LessNumerous bladder-related diseases, including urinary blockages, interstitial cystitis, overactive bladder syndrome, cancer, and infections of the urinary tract, can affect bladder function. The human urinary bladder's distinct anatomy successfully prevents any hazardous material from entering circulation. The pathogenesis was assessed according to the extent of invasion in the bladder wall tissue obtained through Transurethral Resection of Bladder Tumor (TURBT) and classified as Muscle-Invasive and Non-Muscle Invasive Bladder Cancer (MBIC and NMIBC). Intravesical Drug Delivery (IDD) has recently gained attention for treating bladder disorders. IDD refers to the insertion of a drug directly into the bladder using a catheter. Intravesical administration of immunotherapy or chemotherapy has been demonstrated to reduce recurrence rates and inhibit disease progression. In addition, several other systems, including recombinant BCG, gene therapy, vectors, and Antibody-Drug Conjugates (ADCs), are now used. Moreover, the novel intravesical formulations of distinct chemotherapeutic agents, including gemcitabine, Doxorubicin (DOX), and Mitomycin C (MMC), are used in bladder-related problems. Novel intravesical drugs, polymeric hydrogels, dendrimers, hydrogels, mucoadhesives, nanocarriers, and intravesical devices have been discussed. Aside from chemotherapy and immunotherapy, devices such as GemRIS, device-assisted hyperthermic intravesical chemotherapy, and photodynamic therapy are utilized.
-
-
-
Gut-Brain Dialogues in Fruit Fly (Drosophila melanogaster): How Peptide Hormones Bridge Metabolism, Longevity, and Behavioral Adaptation
Authors: Mengzhe Tian, Shushen Sun, Qinghao Meng, Jingyi Li, Xinyi Li, Suxia Ren, Zengyi Huang, Shaoshan Du and Yiwen WangAvailable online: 06 August 2025More LessBackgroundGut-peptide hormones are crucial regulators of various physiological processes, including metabolism, digestion, behavior, and homeostasis. In Drosophila melanogaster, a widely used model organism, a diverse range of gut-peptide hormones governs gut-brain communication, influencing food intake, energy balance, circadian rhythms, stress responses, and aging.
ObjectiveThis review summarizes recent studies on gut-peptide hormones in D. melanogaster, focusing on their mechanisms of action, interactions with other signaling pathways, and their relevance to human orthologs.
MethodsThe PubMed database was searched for studies on gut-peptide hormones in D. melanogaster published in the past decade.
ResultsThe functions of D. melanogaster gut-peptide hormones were reviewed, including DH31, Bursicon (Burs), Tachykinins (Tks), Hedgehog (Hh), Pigment-dispersing factor (PDF), Neuropeptide F (NPF), Short neuropeptide F (sNPF), Allatostatins (ASTs), CCHamides (CCHa), and Limostatin (Lst). These hormones regulate key physiological processes such as digestion, energy homeostasis, and metabolism through conserved pathways.
ConclusionDrosophila melanogaster gut-peptide hormones are fundamental regulators of health and disease. They are conducive to exploring conserved mechanisms for developing treatments against human metabolic and aging disorders.
-
-
-
Role of Artificial Intelligence in Nanomedicine and Organ-specific Therapy: An Updated Review
Available online: 22 July 2025More LessBackgroundIn organ-specific therapy, artificial intelligence (AI) is primarily used to improve surgical planning through image analysis, predict post-transplant outcomes, personalize treatment plans based on patient data, optimize organ allocation logistics, and donor-recipient precision mapping for organs to improve transplants. Furthermore, all these applications ultimately lead to better patient outcomes and enhanced organ therapy.
ObjectiveThis review aims to examine the revolutionary effects of AI in some key healthcare fields, such as nanomedicine, cancer treatment, clinical applications, and organ-specific delivery.
MethodsThis review article discusses in detail the role of AI in nanomedicine, cancer therapy, clinical applications, organ-specific delivery (e.g., cardiovascular, gastroenterology, kidney, liver, lung, ophthalmology, skin, etc.), diagnosis, and radiotherapy. In addition, it also discusses limitations and challenges of AI in healthcare.
ResultsAI-based clinical translation has potential but faces challenges like artifact vulnerability, ethical and legal considerations, and security measures. Restrictive data-use policies may hinder accurate analysis. Regulations and collaboration with data-sharing mechanisms could overcome barriers.
ConclusionAI is being utilized in organ-specific therapy to enhance donor-recipient matching, surgical planning, post-transplant outcomes prediction, and personalized treatment plans by analyzing patient data.
-
-
-
Modern Solutions to UTIs: The Role of Nanotechnology and Herbal Treatments
Authors: Ashutosh Kumar, Amit Kumar, Md Moidul Islam, Ranadeep Borgohain and Sarjana RaikwarAvailable online: 21 July 2025More LessIntroductionUrinary tract infections (UTIs) range from mild to severe cases, commonly caused by uropathogenic Escherichia coli (E. coli). The growing concern about antibiotic resistance demands alternative treatment strategies. Nanotechnology, particularly nanocarriers, presents a promising solution by enhancing drug delivery, antibacterial activity, and targeted therapy. This review focuses on the emerging role of combining herbal remedies with nanotechnology for more effective and personalized management of UTIs, aiming to overcome the limitations of conventional antibiotic therapies.
MethodsThe review involved an extensive search of scientific databases and relevant literature, including studies published to date from PubMed, Science Direct, and Google Scholar. Urinary tract infections (UTI), antibiotic resistance, nanotechnology, drug delivery, targeted drug delivery, and herbal drugs were among the search phrases used.
ResultAccording to studies, combining herbal extracts such as neem and turmeric with nanotechnology significantly enhances antimicrobial activity against UTI pathogens. These nanoformulations show enhanced bacterial inhibition, reduced inflammation, and increased therapeutic precision with minimal side effects.
DiscussionThe synergistic use of herbal remedies and nanocarriers offers a novel approach to managing UTIs. Nanotechnology not only enhances drug delivery but also improves diagnostic accuracy through fluorescence markers and biomolecule tagging. This strategy effectively addresses growing antibiotic resistance and supports the development of personalized treatments. The combination of natural bioactives and advanced delivery systems offers a safer, more effective alternative to conventional antibiotics in treating UTIs.
ConclusionThe integration of nanotechnology and herbal therapies revolutionizes UTI management through precision medicine. This approach enhances treatment efficacy, diagnostic accuracy, and patient outcomes, offering a personalized solution to combat antibiotic resistance and urinary tract abnormalities with improved targeting and minimal side effects.
-
-
-
Innovative Strategies and Advances in Drug Delivery Systems to Address Poor Solubility: A Comprehensive Review
Available online: 21 July 2025More LessPoor solubility remains a significant obstacle in drug administration, adversely affecting the bioavailability and therapeutic efficacy of many drugs. It is also recognized as a primary factor contributing to issues with bioavailability, such as poor, inconsistent, limited, and highly variable bioavailability of marketed products. It is estimated that 40% of marketed drugs face bioavailability challenges primarily due to poor water solubility, and about 90% of pharmacological compounds exhibit poor water solubility in their early development stages. Addressing this issue is crucial for improving drug performance, efficacy, and patient outcomes. This review provides an overview of the challenges associated with poorly soluble drugs, including low bioavailability, limited dissolution rates, inconsistent absorption, decreased patient compliance, formulation difficulties, and associated costs and time constraints. Numerous strategies have been now investigated to tackle the issue of poor solubility. This review offers an updated overview of commonly used macro and nano drug delivery systems, including micelles, nanoemulsions, dendrimers, liposomes, lipid-based delivery systems, microemulsions, cosolvents, polymeric micelle preparation, drug nanocrystals, solid dispersion methods, crystal engineering techniques, and microneedle-based systems. Additionally, the review examines advanced techniques like cyclodextrin-based delivery systems, co-solvency and co-crystallization approaches, polymeric micelles, spray drying, co-precipitation, and amorphous solid dispersion. The role of computational modeling and formulation prediction is also addressed. Recent advancements in protein-based approaches, 3D printing, mesoporous silica nanoparticles, supramolecular delivery systems, magnetic nanoparticles, nanostructured lipid carriers, and lipid-based nanoparticles are highlighted as novel solutions for enhancing the solubility of poorly soluble drugs. The review concludes with predictions for the future, emphasizing the potential for further innovation in drug delivery methods to overcome the challenges associated with poorly soluble drugs.
-
-
-
Therapeutic Drug Monitoring: A New Hope for Individualised Treatment with Venetoclax
Authors: Yue Tang, Shuojiao Li, Peng Rao, Wenxian Yu, Xuanpeng Jiang and Jiatao LiuAvailable online: 16 July 2025More LessB-cell lymphoma-2 (BCL-2) plays a key role in regulating apoptosis. Venetoclax (VEN), a BCL-2 inhibitor, has been approved for the treatment of a variety of hematologic malignancies. VEN is primarily metabolized by CYP3A, and a variety of factors (such as CYP3A inhibitors, as well as food and hepatic functions) have been reported to significantly influence the metabolic process. There is significant interindividual variability in VEN plasma concentrations, and studies have shown that its exposure levels are correlated with efficacy, although the relationship with adverse effects remains controversial. The value of applying of therapeutic drug monitoring (TDM) in individualized VEN therapy has been confirmed by some studies, but the optimal therapeutic window for different malignancies is still unclear. This review summarizes the pharmacokinetic characteristics, along with the factors influencing VEN pharmacokinetics, drug-drug interactions, and advancements in TDM research on VEN, aiming to provide a theoretical basis for TDM-guided individualized therapy.
-
-
-
Crossing Boundaries: A Review of the Diverse Functions of Heterocyclic Compounds in the Management of Cancer and Infectious Diseases
Authors: Pranay Wal, Ankita Wal, Talha Jawaid, Paramita Ganguly, Binit Patel, Pankaj Nainwal, Mohd Qasid Lari, Ajay Kumar and Dileep KumarAvailable online: 09 July 2025More LessIntroduction/ObjectiveHeterocyclic molecules, a mainstay of contemporary medicinal chemistry, are essential in developing antibacterial and anticancer treatments. Their distinct structural features-one or more heteroatoms within the ring-allow for a wide range of biological activities. With a focus on their modes of action and insights into the structure-activity relationship (SAR), this study examines the therapeutic uses of heterocyclic compounds in antibacterial, antifungal, antiviral, and anticancer treatments.
MethodsThe review uses search engines like PubMed and Google Scholar, with a preference for English as the major language, to gather and analyse recent research on the antibacterial and anticancer applications of diverse heterocyclic compounds.
ResultsIt has been discovered that heterocyclic chemicals are useful in blocking microbial enzymes, including DNA gyrase and the machinery involved in protein synthesis. Heterocyclic compounds such as benzimidazoles, quinolines, and acridines have demonstrated noteworthy efficacy in cancer therapy through their targeting of tubulin inhibition, DNA intercalation, and signalling pathways like PI3K/Akt/mTOR and MAPK. The pharmacological characteristics of these compounds were improved by the addition of electron-withdrawing groups, halogenation, and heteroatom replacements, according to SAR investigations.
ConclusionHeterocyclic compounds have great promise for antibacterial and anticancer treatments. They are crucial in drug development because of their structural flexibility, which enables the targeted suppression of vital biological processes. The effectiveness of heterocyclic compounds will continue to be improved by ongoing advancements in drug design and SAR optimization, opening new possibilities for the creation of more potent and selective medicinal treatments.
-
-
-
Matrix Metalloproteinase-9: A Key Diagnostic Biomarker in Cancer Progression
Available online: 04 July 2025More LessMatrix metalloproteinase-9, also known as MMP-9, gelatinase B, or 92 kDa type IV collagenase, is an enzyme that belongs to the matrix metalloproteinase (MMP) family. It is involved in the remodeling of the extracellular matrix in various physiological and pathological processes. MMPs are expressed in low, tightly regulated concentrations; their overexpression or dysregulation can lead to diseases, including cancer. MMP-9 is increasingly recognized as a significant drug target in cancer therapy due to its involvement in tumorigenesis, including processes like cell migration, angiogenesis, and pro-apoptotic and anti-apoptotic activities. Despite MMP-9's significance as a cancer target, developing effective inhibitors remains challenging due to MMP structural similarities. Utilizing MMP-9 as a cancer biomarker could advance cancer diagnosis, prognosis, disease monitoring, recurrence prediction, and other procedures. Biosensors are emerging as pivotal tools in cancer diagnosis and treatment, leveraging their ability to detect specific biomarkers associated with various cancers. Recent advancements have led to the development of both cleavage-based and non-cleavage-based biosensors that enable rapid and sensitive analysis at clinically relevant concentrations of biomarkers while allowing specificity and low detection limits, enhancing point-of-care diagnostics. The cleavage-based biosensors leverage the enzymatic activity of MMP-9, utilizing substrates that are specifically cleaved by MMP-9, while the non-cleavage-based biosensors employ affinity methods, such as antibodies and aptamers for detection. The present review aims to evaluate the role of MMP-9 as a significant biomarker in cancer and its detection through innovative biosensor technologies, while exploring its involvement in various cancer-related processes. This review discusses the significance of MMP-9 in cancer progression, highlighting clinical trials that assess MMP-9 inhibitors as potential therapeutic agents to halt metastatic spread. Furthermore, MMP-9 is detected via biosensors, and insights into the translational potential of MMP-9 both as a biomarker for early cancer detection and a viable target for therapeutic intervention are provided, ultimately contributing to improved patient outcomes in oncology.
-
-
-
GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer
Available online: 04 July 2025More LessIntroductionBreast cancer incidence and mortality have continued to rise over the past few decades. Despite advancements made in clinical research, the most imperative feature of breast cancer management is the diagnosis at the earliest stages. The current focus of the study is to identify and quantify differentially expressed oxidative stress-related proteins as putative early-stage markers for breast cancer.
MethodsNormal and cancerous breast tissue samples (n = 40) were collected after approval from the institutional bioethics committee (IBC) and with patient's consent. A label-free proteomic approach was used to quantify oxidative stress-related proteins. Gene expression of GSTP1, PRDX2, HSP90, NFE2L2, and miR-365a was quantified using RT-qPCR in all samples. Protein expression of PRDX2 and GSTP1 was further analyzed using immunohistochemistry.
ResultsThe protein and gene expression of PRDX2, GSTP1, and HSP90 were significantly upregulated (p < 0.05) in cancerous samples as compared to normal. However, gene and protein expression of the transcription factor NFE2L2 was significantly downregulated (p < 0.05) in diseased samples. OncomiR-365a was also significantly upregulated (p < 0.05) in cancerous samples. Immunohistochemical analysis also confirmed the upregulated expression of GSTP1 and PRDX2 in cancer tissues.
DiscussionOur study provides insight into the significant role of GSTP1, PRDX2, and NFE2L2 in the pathophysiology of the disease as early-stage breast cancer markers. It is suggested that altered expression of these key proteins could play a protective role in reducing the damage.
ConclusionIt can be concluded that GSTP1, PRDX2, and NFE2L2 may serve as predictive early-stage markers for diagnosis and potential therapeutic targets for breast cancer.
-
-
-
RMNet: An RNA m6A Cross-species Methylation Detection Method for Nanopore Sequencing
Authors: Qingwen Li, Chen Sun, Daqian Wang and Jizhong LouAvailable online: 04 July 2025More LessIntroductionN6-methyladenosine (m6A) is the most prevalent RNA modification in eukaryotic cells, influencing RNA lifecycle processes. Existing m6A detection methods, such as wet-lab techniques and statistical approaches, are time-consuming, labor-intensive, or require control samples, while machine learning models often lack cross-species applicability. This study aims to develop RMNet, a robust cross-species m6A detection method using nanopore sequencing.
MethodsRMNet employs Conformer and RNN architectures, integrating signal and alignment features from nanopore sequencing data. Contrastive learning enhances differentiation between m6A and non-m6A sites. The model was trained and tested on datasets from synthesized RNA, Arabidopsis, and human samples, using a single set of model weights.
ResultsRMNet achieved state-of-the-art performance with accuracies of 99.7% for synthesized RNA, 78.8% for Arabidopsis, and 88.9% for human datasets. It outperformed existing methods (m6Anet, DENA, and RedNano) across six metrics, including AUC and AUPR, demonstrating robust cross-species generalization.
DiscussionRMNet’s ability to detect m6A sites across diverse species with a single model addresses limitations of species-specific models. Its high sensitivity and feature representation enable applications in cancer research, neurodevelopmental studies, and plant biology. Limitations include higher error rates in human datasets for thymine-rich k-mers, likely due to complex secondary structures.
ConclusionRMNet provides an efficient, powerful tool for cross-species m6A detection, advancing epitranscriptomics research with potential applications in precision medicine and agricultural science.
-
-
-
The Role of PGE2 in Age-related Diseases
Authors: Jun Guan, Chao Chen, Shanshan Wu and Haihong ZhuAvailable online: 24 June 2025More LessIn the past several years, human life expectancy has increased dramatically, and the global aging process is accelerating at an unprecedented rate. Impaired organ functions and systemic inflammation increase the risk of aging-related diseases. It seriously affects the quality of life in older adults and places a heavy burden on the global economy and public health. Inflammation is the cornerstone of many age-related diseases, and among various inflammatory mediators, Prostaglandin E2 (PGE2) has emerged as a key player. For example, PGE2 could participate in the progression of Alzheimer's disease (AD) by modulating neuroinflammation. Plasma PGE2 is regarded as a potential and specific diagnostic biomarker, and higher initial PGE2 levels are positively correlated with longer survival in AD. PGE2 also mediates bone and muscle metabolism to affect age-related musculoskeletal diseases, including sarcopenia, osteoporosis, and osteoarthritis. It activates the EP4 receptor on sensory nerves to inhibit sympathetic nerve activity and modulate bone formation. Moreover, the PGE2/EP4 axis positively regulates muscle mass and strength. In diabetes, increased Cox-2 and m-PGES2 promote PGE2 production. The activated PGE2/EP3 axis exacerbates the progression of type 2 diabetes (T2D) by impairing glucose metabolism and accelerating β-cell senescence. Therefore, the role of PGE2 in age-related diseases deserves greater attention. Its involvement is driven by the dysregulation of its biosynthesis, metabolism, and receptor-mediated signaling. Regulating the concentration of PGE2 or modulating receptor activity represents a promising therapeutic strategy for managing age-related diseases.
-
-
-
Lipidomics in Breast Cancer: Decoding Metabolic Reprogramming and Unlocking Therapeutic Opportunities
Authors: Harshita Singhai, Sunny Rathee and Umesh K. PatilAvailable online: 24 June 2025More LessLipidomics, a cutting-edge branch of metabolomics provides a comprehensive understanding of the lipidome and its alterations in cellular and systemic processes. In Breast Cancer (BC), a highly heterogeneous disease, lipidomics has emerged as a pivotal tool for exploring metabolic reprogramming, tumor progression, and therapeutic resistance. This review highlights the intricate relationship between lipid metabolism and breast cancer, with a focus on subtype-specific lipid dependencies, oxidative stress, and ferroptosis. Technological advancements, such as mass spectrometry and chromatography, have enabled precise profiling of lipid alterations, revealing distinct lipid signatures across breast cancer subtypes. Key enzymes like acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN), along with lipid regulators like PPARγ, have been identified as central players in lipid-driven tumorigenesis. Lipidomic studies offer the potential for biomarker discovery and the development of lipid-targeted therapies. Despite challenges in standardization and integration with other omics approaches, lipidomics is poised to revolutionize breast cancer diagnostics and therapeutics, providing novel insights into the metabolic underpinnings of this complex disease.
-
-
-
Advancing myloid ggregation esearch: ocus n nnovative Therapies, Molecular Modeling and Nano-Delivery Systems in Alzheimer’s Disease
Authors: Umaira Hasan, Himangini Jain and Ruhi AliAvailable online: 24 June 2025More LessIntroductionAlzheimer’s disease (AD), the most common form of dementia, is a major global health issue. Its complex pathology, including amyloid-beta (Aβ) aggregation, leads to neuronal damage and cognitive decline. Since Aβ plays a major role in AD, therapies targeting its production, aggregation, and clearance are being actively explored. This review discusses recent advances in gene therapy, enzyme inhibitors, molecular modeling, and nano-delivery systems aimed at modifying AD progression, highlighting their potential and challenges.
MethodsThis review compiles findings on BACE1 and γ-secretase inhibitors, gene therapies that modify amyloid metabolism, and combination therapies. Studies have been selected based on their focus on Aβ regulation and their impact on disease progression, cognitive function, and breakthroughs in diagnostics, molecular modeling, and drug delivery for neurodegenerative conditions.
ResultsBACE1 inhibitors, such as verubecestat, and γ-secretase inhibitors, shows potential, however, they face significant challenges related to BBB penetration and adverse effects. Gene therapies using AAV vectors and CRISPR/Cas9 technologies are promising, particularly for individuals genetically predisposed to these diseases. Combination therapies targeting amyloid, tau, and neuro-inflammation have emerged as effective approaches. Advancements in PET, SPECT, MRI, small molecule probes, molecular modeling, and nano-particle-based drug delivery are improving diagnostic and treatment options.
DiscussionThe findings emphasize the multifactorial complexity of amyloid disorders and the limitations of mono-therapies. While certain agents demonstrated efficacy in early disease stages, most treatments have failed in advanced phases due to poor central nervous system (CNS) bioavailability, adverse effects, or insufficient target engagement. Novel delivery systems, combination therapies, and computational design approaches offer enhanced translational potential. However, challenges such as immune responses, delivery efficiency, and off-target effects continue to pose significant barriers.
ConclusionAβ-targeted therapies, including enzyme inhibitors and gene therapies, hold promise, though challenges such as BBB penetration and toxicity still remain. Combination therapies, along with advancements in diagnostics and drug delivery technology, are essential for finding effective treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Future research should prioritize overcoming the persistent barriers to BBB penetration, enhancing therapeutic selectivity, and refining drug delivery systems to enable more precise, targeted interventions, to ultimately reduce the progression of disease at the molecular level.
-
-
-
Neurostimulation for the Management of Epilepsy: Advances in Targeted Therapy
Available online: 27 May 2025More LessBackgroundEpilepsy is a multifaceted neurological disorder marked by seizures that can present with a wide range of symptoms. Despite the prevalent use of anti-epileptic drugs, drug resistance and adverse effects present considerable obstacles. Despite advancements in anti-epileptic drugs (AEDs), approximately 20-30% of patients remain drug-resistant, highlighting the need for innovative therapeutic strategies.
AimThis study aimed to explore advancements in epilepsy diagnosis and treatment utilizing modern technology and medicines.
MethodsThe literature survey was carried out using Scopus, ScienceDirect, and Google Scholar. Data from the last 10 years were preferred to include in the study.
ResultEmerging technologies, such as artificial intelligence, gene therapy, and wearable gadgets, have transformed epilepsy care. EEG and MRI play essential roles in diagnosis, while AI aids in evaluating big datasets for more accurate seizure identification. Machine learning and artificial intelligence are increasingly integrated into diagnostic processes to enhance seizure detection and classification. Wearable technology improves patient self-monitoring and helps clinical research. Furthermore, gene treatments offer promise by treating the fundamental causes of seizure activity, while stem cell therapies give neuroprotective and regenerative advantages. Dietary interventions, including ketogenic diets, are being examined for their ability to modify neurochemical pathways implicated in epilepsy.
ConclusionRecent technological and therapeutic developments provide major benefits in epilepsy assessment and treatment, with AI and wearable devices enhancing seizure detection and patient monitoring. Nonetheless, additional study is essential to ensure greater clinical application and efficacy. Future perspectives include the potential of optogenetics and advanced signal processing techniques to revolutionize treatment paradigms, emphasizing the importance of personalized medicine in epilepsy care. Overall, a comprehensive understanding of the multifaceted nature of epilepsy is essential for developing effective interventions and improving patient outcomes.
-
-
-
RAAS Overactivation and Mitochondrial Damage Signaling as Key Players in Lethal COVID-19
Authors: Sabrina Fulkerson, Grace Hohman, Tyler Stark, Selman Aydogdu and Mohamed EldeebAvailable online: 27 May 2025More LessCoronavirus disease 2019 (COVID-19), which led to a global pandemic causing millions of deaths, is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While previous research on COVID-19 has primarily utilized nasal swabs and blood samples, these do not provide comprehensive insights into all the organ systems affected by the infection. A recent study by Topper et al. addressed this gap by analyzing both nasal samples and autopsy tissues from SARS-CoV-2-infected individuals. Their findings highlight a significant role of mitochondrial damage pathways and RAAS overactivation in contributing to the severity of SARS- CoV-2 infections. Importantly, targeting mitochondrial dysfunction and RAAS overactivation pathways may offer promising and specific druggable targets for treating COVID-19 patients.
-
-
-
Therapeutic Aspects of Melatonin-sirtuin Crosstalk: An Updated Review of Current Data Based on Cellular Mechanisms
Available online: 14 May 2025More LessMelatonin, a master regulator of circadian rhythms and diverse physiological processes, exhibits complex interactions with various molecules. Sirtuins, a family of histone deacetylases, are key players in aging, stress responses, and metabolism and represent a critical target for melatonin. This review explores the multifaceted functions of melatonin and sirtuins, delving into the molecular mechanisms of their interaction. We further examine the impact of this synergy on various pathologies across different organs. Studies suggest that melatonin modulates SIRT1 and SIRT3 signaling pathways, offering protection in neurodegenerative, cardiovascular, skeletal, and pulmonary diseases, as well as renal and hepatic dysfunction. Additionally, melatonin-sirtuin interactions have been implicated in mitigating cancer development and promoting health in the female and male reproductive systems. Notably, the majority of studies across these systems demonstrate melatonin's ability to regulate SIRT1 and SIRT3 signaling, thereby alleviating associated pathologies. In conclusion, the intricate interplay between melatonin and, particularly, SIRT1 and SIRT3 emerges as a crucial modulator of diverse signaling pathways, with promising therapeutic implications for a wide range of diseases.
-
-
-
IL-17 Antagonists as a Promising Therapeutic Modality for Hidradenitis Suppurativa
Authors: Piotr K. Krajewski and Jacek C. SzepietowskiAvailable online: 30 April 2025More LessHidradenitis suppurativa (HS) is an inflammatory, debilitating skin disorder affecting primarily young adults [1]. The course of the disease is chronic, with recurrent flares of inflammatory nodules, abscesses, and inflammatory tunnels localized mainly in the intertriginous areas [1]. It has been studied that HS, characterized by a high severity of pain and constant purulent discharge, has an enormous impact on a patient’s quality of life and is often associated with depression, anxiety, stigmatization, workplace challenges, and suicidal ideations [2, 3]. Due to the unknown pathogenesis and HS’s multifactorial nature, the treatment is difficult and often unsatisfactory for clinicians and patients [1, 4].
-
-
-
Microwave-assisted Green Synthesis: An Approach for the Development of Anti-tubercular Agents
Available online: 23 April 2025More LessTuberculosis (TB) is a serious infectious disease that primarily affects the lungs but can also spread to the brain and spine. The highly pathogenic bacteria that causes TB is called Mycobacterium tuberculosis (Mtb). Usually, when an infected person coughs, sneezes, or speaks, the disease spreads through the air. TB is treatable with antibiotics, but it requires a long course of treatment, usually 6 to 9 months to eliminate the bacteria and prevent drug resistance. Thus, developing novel anti-tubercular therapeutics with various structural classes is necessary to solve the problems brought on by strains that are resistant to several currently available therapies.
Resistance to widely used anti-tubercular drugs is increasing daily. As a result, continuing medication therapy is necessary to stop more microbial infections. However, it leads to treatment resistance, which increases the likelihood that the disease may resurface in immune-compromised patients. Several anti-tubercular medications with various molecular structures show appropriate anti-tubercular action against Mycobacterium TB strains that are drug-sensitive and drug-resistant. Compared to conventional synthetic methods, synthetic reactions can be carried out more effectively and selectively under simple reaction conditions by employing microwave radiation. Microwave-assisted organic synthesis (MAOS) is a useful method for increasing product yield and selectivity while accelerating the reaction rate for different types of organic synthesis. Several lead compounds with anti-tubercular properties that were synthesized using the microwave irradiation (MWI) approach are discussed in the current work.
-
-
-
Emerging Carbon Dots Nanomaterials for Ovarian Cancer Diagnosis and Therapy
Available online: 04 February 2025More LessDelayed diagnosis and limited treatment options make ovarian cancer difficult to treat. This paper examines the growing role of Carbon Dots (CDs) in ovarian cancer diagnosis and treatment. Photoluminescence and biocompatibility make CDs ideal for biomedical use. We emphasize their ability to improve fluorescence and molecular imaging in imaging and diagnostics. We also demonstrate the efficacy of carbon dots in targeted drug delivery systems in overcoming drug resistance and improving therapeutic outcomes. Photodynamic and photothermal therapies are used to show that CDs can treat hypoxic ovarian cancer tumours. We also discuss CD safety issues and constraints, emphasising the need for thorough assessments and fine-tuning. Future research focuses on personalised medicine and CD integration with other therapies. This text concludes by discussing CDs' clinical use and the challenges of production and regulatory approval. CDs can improve ovarian cancer diagnosis and treatment, improving patient outcomes and survival.
-